Emergent BioSolutions (EBS) Cash & Current Investments (2010 - 2026)

Emergent BioSolutions' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $161.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 5.69% year-over-year to $161.5 million; the TTM figure through Mar 2026 stood at $161.5 million (up 5.69% YoY), while the FY2025 annual figure was $209.1 million, up 98.01% from the prior year.
• Cash & Current Investments was $161.5 million for Q1 2026 at Emergent BioSolutions, down from $209.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $642.6 million in Q4 2022 to a low of $71.0 million in Q2 2024.
• Historically, Cash & Current Investments has averaged $226.6 million across 5 years, with a median of $161.5 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments slumped 82.62% in 2023, then soared 281.69% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $642.6 million in 2022, then plunged by 82.62% to $111.7 million in 2023, then decreased by 5.46% to $105.6 million in 2024, then jumped by 98.01% to $209.1 million in 2025, then decreased by 22.76% to $161.5 million in 2026.
• The last three Cash & Current Investments figures came in at $161.5 million (Q1 2026), $209.1 million (Q4 2025), and $249.2 million (Q3 2025), per Business Quant data.